Literature DB >> 20070866

Altered apolipoprotein E glycosylation is associated with Abeta(42) accumulation in an animal model of Niemann-Pick Type C disease.

Ching-Ching Chua1, Mei-Li Lim, Boon-Seng Wong.   

Abstract

Neurodegeneration is the final cause of death in Niemann-Pick Type C (NPC) disease, a cholesterol-storage disorder. Accumulating evidence indicates that NPC may share common pathological mechanisms with Alzheimer's disease, including the link between aberrant cholesterol metabolism and amyloid-beta (Abeta) deposition. Apolipoprotein E (apoE) is highly expressed in the brain and plays a pivotal role in cholesterol metabolism. ApoE can also modulate Abeta production and clearance, and it is a major genetic risk factor for Alzheimer's disease. Although apoE is glycosylated, the functional significance of this chemical alteration on Abeta catabolism is unclear. In this study using an NPC animal model, we detect specific changes in apoE glycosylation that correlate with increased Abeta(42) accumulation prior to the appearance of neurological abnormalities. This suggests that increased apoE expression could be a compensatory response to the increased Abeta(42) deposition in NPC(nih) mice. We also observe what appears to be a simplification of the glycosylation process on apoE during neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070866     DOI: 10.1111/j.1471-4159.2010.06586.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's.

Authors:  Ivan A Borbon; Robert P Erickson
Journal:  J Appl Genet       Date:  2010-12-18       Impact factor: 3.240

Review 2.  Cell-specific production, secretion, and function of apolipoprotein E.

Authors:  Maaike Kockx; Mathew Traini; Leonard Kritharides
Journal:  J Mol Med (Berl)       Date:  2018-03-07       Impact factor: 4.599

Review 3.  Golgi glycosylation and human inherited diseases.

Authors:  Hudson H Freeze; Bobby G Ng
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-09-01       Impact factor: 10.005

4.  Abnormal LAMP1 glycosylation may play a role in Niemann-Pick disease, type C pathology.

Authors:  Niamh X Cawley; Caitlin Sojka; Antony Cougnoux; Anna T Lyons; Elena-Raluca Nicoli; Christopher A Wassif; Forbes D Porter
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

5.  Complex N-Linked Glycosylation: A Potential Modifier of Niemann-Pick Disease, Type C1 Pathology.

Authors:  Niamh X Cawley; Anna T Lyons; Daniel Abebe; Rachel Luke; Julia Yerger; Rebecca Telese; Christopher A Wassif; Joan E Bailey-Wilson; Forbes D Porter
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

Review 6.  Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin.

Authors:  Jean E Vance; Barbara Karten
Journal:  J Lipid Res       Date:  2014-03-24       Impact factor: 5.922

7.  Simple and Fast Assay for Apolipoprotein E Phenotyping and Glycotyping: Discovering Isoform-Specific Glycosylation in Plasma and Cerebrospinal Fluid.

Authors:  Yueming Hu; Cristiana Meuret; Scholastica Go; Hussein N Yassine; Dobrin Nedelkov
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 8.  Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat.

Authors:  Mark Walterfang; Yin-Hsiu Chien; Jackie Imrie; Derren Rushton; Danielle Schubiger; Marc C Patterson
Journal:  Orphanet J Rare Dis       Date:  2012-10-06       Impact factor: 4.123

9.  Proteomic Analysis of Plasma from California Sea Lions (Zalophus californianus) Reveals Apolipoprotein E as a Candidate Biomarker of Chronic Domoic Acid Toxicosis.

Authors:  Benjamin A Neely; Jason A Ferrante; J Mauro Chaves; Jennifer L Soper; Jonas S Almeida; John M Arthur; Frances M D Gulland; Michael G Janech
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.